Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03283917 · ClinicalTrials.gov registry record · Phase 1
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
A Phase 1 study of Newly Diagnosed Primary Amyloidosis and Recurrent Primary Amyloidosis, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT03283917 is a Phase 1 study of Newly Diagnosed Primary Amyloidosis and Recurrent Primary Amyloidosis that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03283917, a Phase 1 study of Newly Diagnosed Primary Amyloidosis and Recurrent Primary Amyloidosis, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of daratumumab, ixazomib, and dexamethasone in treating participants with amyloid light chain amyloidosis. Monoclonal antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab, ixazomib, and dexamethasone may be effective in treating participants with light chain amyloidosis.
Conditions Studied
Interventions
- DRUG Dexamethasone
- BIOLOGICAL Daratumumab
- DRUG Ixazomib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2027-05-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03283917
The ClinicalTrials.gov registry entry for NCT03283917 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Newly Diagnosed Primary Amyloidosis appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03283917 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03283917 about?
NCT03283917 is a clinical study titled "Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis". This phase I trial studies the side effects and best dose of daratumumab, ixazomib, and dexamethasone in treating participants with amyloid light chain amyloidosis. Monoclonal antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherap...
What is the current status of trial NCT03283917?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2018-02-07. Estimated completion is 2027-05-18.
What conditions does trial NCT03283917 study?
This clinical trial studies the following conditions: Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis.
What interventions are being tested in trial NCT03283917?
The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (BIOLOGICAL), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT03283917?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03283917 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.